BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19399788)

  • 1. Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts.
    Jantscheff P; Esser N; Graeser R; Ziroli V; Kluth J; Unger C; Massing U
    Prostate; 2009 Aug; 69(11):1151-63. PubMed ID: 19399788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging.
    Bornmann C; Graeser R; Esser N; Ziroli V; Jantscheff P; Keck T; Unger C; Hopt UT; Adam U; Schaechtele C; Massing U; von Dobschuetz E
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):395-405. PubMed ID: 17554540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.
    Moog R; Burger AM; Brandl M; Schüler J; Schubert R; Unger C; Fiebig HH; Massing U
    Cancer Chemother Pharmacol; 2002 May; 49(5):356-66. PubMed ID: 11976829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer.
    Graeser R; Bornmann C; Esser N; Ziroli V; Jantscheff P; Unger C; Hopt UT; Schaechtele C; von Dobschuetz E; Massing U
    Pancreas; 2009 Apr; 38(3):330-7. PubMed ID: 19142174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model.
    Jantscheff P; Ziroli V; Esser N; Graeser R; Kluth J; Sukolinskaya A; Taylor LA; Unger C; Massing U
    Clin Exp Metastasis; 2009; 26(8):981-92. PubMed ID: 19784785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1.
    Zhao XY; Nie CL; Liang SF; Yuan Z; Deng HX; Wei YQ
    Biomed Pharmacother; 2012 Dec; 66(8):597-602. PubMed ID: 23153503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice.
    Jia L; Zhang MH; Yuan SZ; Huang WG
    World J Gastroenterol; 2005 Jan; 11(3):447-50. PubMed ID: 15637766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells.
    Kanzaki M; Kakinuma H; Kumazawa T; Inoue T; Saito M; Narita S; Yuasa T; Tsuchiya N; Habuchi T
    Oncol Rep; 2007 Apr; 17(4):761-7. PubMed ID: 17342312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
    Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
    Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
    Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity.
    Dalla Pozza E; Lerda C; Costanzo C; Donadelli M; Dando I; Zoratti E; Scupoli MT; Beghelli S; Scarpa A; Fattal E; Arpicco S; Palmieri M
    Biochim Biophys Acta; 2013 May; 1828(5):1396-404. PubMed ID: 23384419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy.
    Rayburn ER; Wang W; Zhang Z; Li M; Zhang R; Wang H
    Prostate; 2006 Nov; 66(15):1653-63. PubMed ID: 16927305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).
    Morant R; Bernhard J; Maibach R; Borner M; Fey MF; Thürlimann B; Jacky E; Trinkler F; Bauer J; Zulian G; Hanselmann S; Hürny C; Hering F
    Ann Oncol; 2000 Feb; 11(2):183-8. PubMed ID: 10761753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer.
    Cosco D; Bulotta A; Ventura M; Celia C; Calimeri T; Perri G; Paolino D; Costa N; Neri P; Tagliaferri P; Tassone P; Fresta M
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1009-20. PubMed ID: 19263052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of magnetic gemcitabine stealth nano-liposomes on the characteristics of breast cancer cell line MCF-7].
    Tong Q; Shu XG; Lu XM; Li WY; Tao KX; Chen DD; Wang GB
    Yao Xue Xue Bao; 2009 Feb; 44(2):181-7. PubMed ID: 19408690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic.
    Papa AL; Sidiqui A; Balasubramanian SU; Sarangi S; Luchette M; Sengupta S; Harfouche R
    Cell Oncol (Dordr); 2013 Dec; 36(6):449-57. PubMed ID: 24081907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
    Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
    Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.
    Thoennissen NH; Iwanski GB; Doan NB; Okamoto R; Lin P; Abbassi S; Song JH; Yin D; Toh M; Xie WD; Said JW; Koeffler HP
    Cancer Res; 2009 Jul; 69(14):5876-84. PubMed ID: 19605406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
    Singh A; Xu J; Mattheolabakis G; Amiji M
    Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.